First case of A859T epidermal growth factor receptor mutation responding to erlotinib

J Thorac Oncol. 2011 Mar;6(3):639-40. doi: 10.1097/JTO.0b013e3182037c0c.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics
  • Adenocarcinoma / secondary
  • Adrenal Gland Neoplasms / drug therapy*
  • Adrenal Gland Neoplasms / genetics
  • Adrenal Gland Neoplasms / secondary
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / secondary
  • DNA, Neoplasm / genetics
  • ErbB Receptors / genetics*
  • Erlotinib Hydrochloride
  • Exons / genetics
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Middle Aged
  • Mutation / genetics*
  • Polymerase Chain Reaction
  • Positron-Emission Tomography
  • Protein Kinase Inhibitors / therapeutic use
  • Quinazolines / therapeutic use*
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • DNA, Neoplasm
  • Protein Kinase Inhibitors
  • Quinazolines
  • Erlotinib Hydrochloride
  • EGFR protein, human
  • ErbB Receptors